The IRF family of transcription factors

Members of the interferon-regulatory factor (IRF) proteins family were originally identified as transcriptional regulators of the Type I interferon system. Thanks to consistent advances made in our understanding of the immunobiology of innate receptors, it is now clear that several IRFs are critical for the elicitation of innate pattern recognition receptors, and—as a consequence—for adaptive immunity. In addition, IRFs have attracted great attentions as they modulate cellular responses that are involved in tumorigenesis. The regulation of oncogenesis by IRFs has important implications for understanding the host susceptibility to several Types of cancers, their progression, as well as the potential for therapeutic interventions.

[1]  Chunliu Zhu,et al.  The Interferon Consensus Sequence-binding Protein (ICSBP/IRF8) Represses PTPN13 Gene Transcription in Differentiating Myeloid Cells* , 2008, Journal of Biological Chemistry.

[2]  M. Lovett,et al.  Abnormal skin, limb and craniofacial morphogenesis in mice deficient for interferon regulatory factor 6 (Irf6) , 2006, Nature Genetics.

[3]  G. Stein,et al.  Cell Cycle Regulation of Histone H4 Gene Transcription Requires the Oncogenic Factor IRF-2* , 1998, The Journal of Biological Chemistry.

[4]  K. Strasser-Weippl,et al.  Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma , 2008, Leukemia.

[5]  P. Sideras,et al.  Low expression of interferon regulatory factor‐1 and identification of novel exons skipping in patients with chronic myeloid leukaemia , 2002, British journal of haematology.

[6]  M. Schmidt,et al.  Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha. , 2001, Blood.

[7]  J. Hiscott,et al.  In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors. , 2002, Cancer research.

[8]  Paul Shinn,et al.  Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. , 2012, Cancer cell.

[9]  K. Hölzle,et al.  Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region , 2005, Nucleic acids research.

[10]  J. Pagano.  Epstein-Barr virus: the first human tumor virus and its role in cancer. , 1999, Proceedings of the Association of American Physicians.

[11]  D. Levy,et al.  Inhibition of Interferon Regulatory Factor 7 (IRF7)-Mediated Interferon Signal Transduction by the Kaposi's Sarcoma-Associated Herpesvirus Viral IRF Homolog vIRF3 , 2007, Journal of Virology.

[12]  E. Appella,et al.  Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes. , 1992, The Journal of biological chemistry.

[13]  C. Tunyaplin,et al.  ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells. , 2003, Blood.

[14]  A. Bowie,et al.  Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors. , 2004, The Journal of biological chemistry.

[15]  D. Levy,et al.  Interferon-alpha regulates nuclear translocation and DNA-binding affinity of ISGF3, a multimeric transcriptional activator. , 1990, Genes & development.

[16]  B. Marinari,et al.  A regulatory feedback loop involving p63 and IRF6 links the pathogenesis of 2 genetically different human ectodermal dysplasias. , 2010, The Journal of clinical investigation.

[17]  Zhijian J. Chen,et al.  Antiviral innate immunity pathways , 2006, Cell Research.

[18]  A. Feldman,et al.  Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas , 2008, Leukemia.

[19]  T. Taniguchi,et al.  Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity , 1997, Oncogene.

[20]  K. Honda,et al.  Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. , 2003, Nature.

[21]  L. Hofbauer,et al.  Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. , 2004, Blood.

[22]  L. Staudt,et al.  IRF4: Immunity. Malignancy! Therapy? , 2009, Clinical Cancer Research.

[23]  A. Dolnikov,et al.  A retroviral library genetic screen identifies IRF-2 as an inhibitor of N-ras-induced growth suppression in leukemic cells , 2005, Oncogene.

[24]  K. C. Oliveira,et al.  Analysis of Schistosoma mansoni genes shared with Deuterostomia and with possible roles in host interactions , 2007, BMC Genomics.

[25]  T. Taniguchi,et al.  Suppression of c-myc or fosB-induced cell transformation by the transcription factor IRF-1. , 1994, Cancer Letters.

[26]  Kebin Liu,et al.  Coordinate Regulation of IFN Consensus Sequence-Binding Protein and Caspase-1 in the Sensitization of Human Colon Carcinoma Cells to Fas-Mediated Apoptosis by IFN-γ , 2003, The Journal of Immunology.

[27]  K. Ozato,et al.  Interferon Regulatory Factor-2 Regulates Cell Growth through Its Acetylation* , 2003, Journal of Biological Chemistry.

[28]  M. Offermann.  Kaposi sarcoma herpesvirus-encoded interferon regulator factors. , 2007, Current topics in microbiology and immunology.

[29]  Paul J Hertzog,et al.  Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape , 2012, Nature Medicine.

[30]  J Isola,et al.  Molecular cytogenetics of primary breast cancer by CGH , 1998, Genes, chromosomes & cancer.

[31]  M. Hardy,et al.  Interferon Regulatory Factor 3 Is a Cellular Partner of Rotavirus NSP1 , 2002, Journal of Virology.

[32]  D. Kalvakolanu,et al.  The interferon-inducible murine p48 (ISGF3g) gene is regulated by protooncogene c-myc (transcriptionycell growthycytotoxic drugsyresistance) , 1997 .

[33]  A. Bowie,et al.  Poxvirus Protein N1L Targets the I-κB Kinase Complex, Inhibits Signaling to NF-κB by the Tumor Necrosis Factor Superfamily of Receptors, and Inhibits NF-κB and IRF3 Signaling by Toll-like Receptors* , 2004, Journal of Biological Chemistry.

[34]  Hideo Negishi,et al.  IRF-7 is the master regulator of type-I interferon-dependent immune responses , 2005, Nature.

[35]  T. Taniguchi,et al.  Loss of transcription factor IRF-1 affects tumor susceptibility in mice carrying the Ha-ras transgene or nullizygosity for p53. , 1999, Genes & development.

[36]  T. Taniguchi,et al.  Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-β gene regulatory elements , 1988, Cell.

[37]  M. Barro,et al.  Rotavirus NSP1 Inhibits Expression of Type I Interferon by Antagonizing the Function of Interferon Regulatory Factors IRF3, IRF5, and IRF7 , 2007, Journal of Virology.

[38]  J. Pagano,et al.  TRAF6 and the Three C-Terminal Lysine Sites on IRF7 Are Required for Its Ubiquitination-Mediated Activation by the Tumor Necrosis Factor Receptor Family Member Latent Membrane Protein 1 , 2008, Molecular and Cellular Biology.

[39]  Michael G Tovey,et al.  GAAP‐1: a transcriptional activator of p53 and IRF‐1 possesses pro‐apoptotic activity , 2002, EMBO reports.

[40]  M. Colonna.  TLR pathways and IFN‐regulatory factors: To each its own , 2007, European journal of immunology.

[41]  K. Ozato,et al.  Inhibition of p300 Histone Acetyltransferase by Viral Interferon Regulatory Factor , 2000, Molecular and Cellular Biology.

[42]  S. Namkoong,et al.  Interferon regulatory factor‐1 mediates interferon‐γ‐induced apoptosis in ovarian carcinoma cells , 2002 .

[43]  J. Hiscott,et al.  Transcription factor IRF-2 exerts its oncogenic phenotype through the DNA binding/transcription repression domain. , 1995, Oncogene.

[44]  T. Taniguchi,et al.  An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes , 1995, Nature.

[45]  T. Taniguchi,et al.  Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE). , 1995, Nucleic acids research.

[46]  T. Taniguchi,et al.  The IRF family transcription factors in immunity and oncogenesis. , 2008, Annual review of immunology.

[47]  C. Der,et al.  Interferon Regulatory Factor 7 Is Associated with Epstein-Barr Virus-Transformed Central Nervous System Lymphoma and Has Oncogenic Properties , 2004, Journal of Virology.

[48]  A. Karpova,et al.  Identification of TRAIL as an Interferon Regulatory Factor 3 Transcriptional Target , 2005, Journal of Virology.

[49]  U. Storb,et al.  Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator. , 1995, Genes & development.

[50]  Jong-Sup Park,et al.  Inactivation of Interferon Regulatory Factor-1 Tumor Suppressor Protein by HPV E7 Oncoprotein , 2000, The Journal of Biological Chemistry.

[51]  Hideo Negishi,et al.  Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence , 2003, Nature.

[52]  T. Taniguchi,et al.  The oncogenic transcription factor IRF-2 possesses a transcriptional repression and a latent activation domain. , 1994, Oncogene.

[53]  A. Bielawska,et al.  IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia. , 2011, Cancer research.

[54]  Mary J. C. Hendrix,et al.  Interferon Regulatory Factor 6 Promotes Cell Cycle Arrest and Is Regulated by the Proteasome in a Cell Cycle-Dependent Manner , 2008, Molecular and Cellular Biology.

[55]  J. Russo,et al.  Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[56]  N. Reich,et al.  Apoptosis is promoted by the dsRNA‐activated factor (DRAF1) during viral infection independent of the action of interferon or p53 , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[57]  J. Darnell,et al.  Cytoplasmic activation of ISGF3, the positive regulator of interferon-alpha-stimulated transcription, reconstituted in vitro. , 1989, Genes & development.

[58]  P. Pitha,et al.  Functional Analysis of Human Herpesvirus 8-Encoded Viral Interferon Regulatory Factor 1 and Its Association with Cellular Interferon Regulatory Factors and p300 , 1999, Journal of Virology.

[59]  B. Barnes,et al.  Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death. , 2005, Cancer research.

[60]  M. Lung,et al.  Epigenetic disruption of interferon-γ response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas , 2008, Oncogene.

[61]  C. Boshoff,et al.  Molecular Mimicry of Human Cytokine and Cytokine Response Pathway Genes by KSHV , 1996, Science.

[62]  al. et,et al.  Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia , 1993, Science.

[63]  T. Taniguchi,et al.  Functionally inactivating point mutation in the tumor‐suppressor IRF‐1 gene identified in human gastric cancer , 1998, International journal of cancer.

[64]  T. Taniguchi,et al.  Crystal structure of an IRF‐DNA complex reveals novel DNA recognition and cooperative binding to a tandem repeat of core sequences , 1999, The EMBO journal.

[65]  T. Taniguchi,et al.  Interferon regulatory factor family of transcription factors and regulation of oncogenesis , 2008, Cancer science.

[66]  B. Klein,et al.  Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma , 1997, Nature Genetics.

[67]  Lucia Gabriele,et al.  The feedback phase of type I interferon induction in dendritic cells requires interferon regulatory factor 8. , 2007, Immunity.

[68]  Michael O. Kelleher,et al.  Role of Mdm2 acid domain interactions in recognition and ubiquitination of the transcription factor IRF-2. , 2009, The Biochemical journal.

[69]  J. Hiscott,et al.  The IRF-3 Transcription Factor Mediates Sendai Virus-Induced Apoptosis , 2000, Journal of Virology.

[70]  Jeffrey C. Murray,et al.  Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes , 2002, Nature Genetics.

[71]  S. Joshi,et al.  IRF4 Is a Suppressor of c-Myc Induced B Cell Leukemia , 2011, PloS one.

[72]  Y. Yatabe,et al.  Aberrant expression of interferon regulatory factor 3 in human lung cancer. , 2010, Biochemical and biophysical research communications.

[73]  Borivoj Vojtesek,et al.  A Multiprotein Binding Interface in an Intrinsically Disordered Region of the Tumor Suppressor Protein Interferon Regulatory Factor-1* , 2011, The Journal of Biological Chemistry.

[74]  T. Akaike,et al.  IRF-1 is an essential mediator in IFN-gamma-induced cell cycle arrest and apoptosis of primary cultured hepatocytes. , 1999, Biochemical and biophysical research communications.

[75]  T. Taniguchi,et al.  Distinct and Essential Roles of Transcription Factors IRF-3 and IRF-7 in Response to Viruses for IFN-α/β Gene Induction , 2000 .

[76]  Qiang Sun,et al.  Functional Analysis of a Dominant Negative Mutation of Interferon Regulatory Factor 5 , 2009, PloS one.

[77]  T. Taniguchi,et al.  IRF family of transcription factors as regulators of host defense. , 2001, Annual review of immunology.

[78]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.

[79]  P. Pitha,et al.  The IRF family, revisited. , 2007, Biochimie.

[80]  M Kitagawa,et al.  Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2 , 1993, Science.

[81]  K. Honda,et al.  Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression , 2007, Proceedings of the National Academy of Sciences.

[82]  M. Vidal,et al.  Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. , 1998, Genes & development.

[83]  M. Schmidt,et al.  Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  N. Clarke,et al.  A ChIP–chip approach reveals a novel role for transcription factor IRF1 in the DNA damage response , 2009, Nucleic acids research.

[85]  Michael J Dixon,et al.  Irf6 is a key determinant of the keratinocyte proliferation-differentiation switch , 2006, Nature Genetics.

[86]  H. Hausen.  Papillomaviruses and cancer: from basic studies to clinical application , 2002, Nature Reviews Cancer.

[87]  J. Hiscott,et al.  The growing family of interferon regulatory factors. , 1997, Cytokine & growth factor reviews.

[88]  T. Taniguchi,et al.  Regulation of immunity and oncogenesis by the IRF transcription factor family , 2010, Cancer Immunology, Immunotherapy.

[89]  Yusuke Nakamura,et al.  Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53 , 2002, Oncogene.

[90]  R. Césaire,et al.  Repression of DNA repair mechanisms in IRF-4-expressing and HTLV-I-infected T lymphocytes. , 2005, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[91]  N. Rohland,et al.  The Kaposi's Sarcoma-associated Herpesvirus-encoded vIRF-3 Inhibits Cellular IRF-5* , 2009, Journal of Biological Chemistry.

[92]  M. Karin,et al.  The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4 , 2004, Nature.

[93]  S. Nishizuka,et al.  Two distinct regions of deletion on the long arm of chromosome 5 in differentiated adenocarcinomas of the stomach. , 1996, Cancer research.

[94]  H. Kwon,et al.  Interferon regulatory factors: the next generation. , 1999, Gene.

[95]  E. Kieff,et al.  IRF7 activation by Epstein–Barr virus latent membrane protein 1 requires localization at activation sites and TRAF6, but not TRAF2 or TRAF3 , 2008, Proceedings of the National Academy of Sciences.

[96]  M. Hameed,et al.  Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis , 2011, Breast Cancer Research.

[97]  R. Hrdličková,et al.  Dynamic evolution of immune system regulators: the history of the interferon regulatory factor family. , 2009, Molecular biology and evolution.

[98]  G. Daley,et al.  Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia. , 2001, Blood.

[99]  Kyoungsook Park,et al.  Elevated level of SUMOylated IRF-1 in tumor cells interferes with IRF-1-mediated apoptosis , 2007, Proceedings of the National Academy of Sciences.

[100]  M. Hendrix,et al.  IRF6 in development and disease: A mediator of quiescence and differentiation , 2008, Cell cycle.

[101]  H. Hauser,et al.  Protein-protein and DNA-protein interactions affect the activity of lymphoid-specific IFN regulatory factors. , 1999, Journal of immunology.

[102]  V. Bilim,et al.  Role of IRF‐1 and caspase‐7 in IFN‐γ enhancement of Fas‐mediated apoptosis in ACHN renal cell carcinoma cells , 2003 .

[103]  L. Cantley,et al.  Interferon regulatory factor-3 is an in vivo target of DNA-PK , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[104]  G. Doherty,et al.  Interferon Regulatory Factor Expression in Human Breast Cancer , 2001, Annals of surgery.

[105]  P. Pitha,et al.  Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. , 2003, Cancer research.

[106]  K. Honda,et al.  IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors , 2006, Nature Reviews Immunology.

[107]  J. Yim,et al.  Oncogenic Potential of a Dominant Negative Mutant of Interferon Regulatory Factor 3* , 2003, The Journal of Biological Chemistry.

[108]  D. Xie,et al.  IRF-2 is over-expressed in pancreatic cancer and promotes the growth of pancreatic cancer cells , 2012, Tumor Biology.

[109]  E. Appella,et al.  An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[110]  T. Taniguchi,et al.  Accelerated exon skipping of IRF-1 mRNA in human myelodysplasia/leukemia; a possible mechanism of tumor suppressor inactivation. , 1994, Oncogene.

[111]  P. Pitha,et al.  Functional Analysis of Human Herpesvirus 8-Encoded Viral Interferon Regulatory Factor 1 and Its Association with Cellular Interferon Regulatory Factors and p 300 , 1999 .

[112]  P. Tailor,et al.  The Interferon Regulatory Factor Family in Host Defense: Mechanism of Action* , 2007, Journal of Biological Chemistry.

[113]  G. Dotto,et al.  IRF6 is a mediator of Notch pro‐differentiation and tumour suppressive function in keratinocytes , 2011, The EMBO journal.

[114]  T. Taniguchi,et al.  Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage , 1996, Nature.

[115]  Takashi Miyata,et al.  Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes , 1989, Cell.

[116]  J. Waring,et al.  Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. , 1998, Blood.

[117]  P. Tailor,et al.  Interferon Regulatory Factor-8 Is Indispensable for the Expression of Promyelocytic Leukemia and the Formation of Nuclear Bodies in Myeloid Cells* , 2007, Journal of Biological Chemistry.

[118]  P. Pitha,et al.  Unique properties of a second human herpesvirus 8-encoded interferon regulatory factor (vIRF-2). , 1999, Journal of human virology.

[119]  A. Bowie,et al.  Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKε‐mediated IRF activation , 2008, The EMBO journal.

[120]  J. Waring,et al.  Immunodeficiency and Chronic Myelogenous Leukemia-like Syndrome in Mice with a Targeted Mutation of the ICSBP Gene , 1996, Cell.

[121]  T. Taniguchi,et al.  A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes , 1996, Molecular and cellular biology.

[122]  S. Imbeaud,et al.  Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma , 2012, Nature Genetics.

[123]  T. Taniguchi,et al.  Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1 , 1994, Cell.

[124]  R. Ren,et al.  Expression of Interferon Consensus Sequence Binding Protein (ICSBP) Is Downregulated in Bcr-Abl-Induced Murine Chronic Myelogenous Leukemia-Like Disease, and Forced Coexpression of ICSBP Inhibits Bcr-Abl-Induced Myeloproliferative Disorder , 2000, Molecular and Cellular Biology.

[125]  A. Dolnikov,et al.  N-ras-induced growth suppression of myeloid cells is mediated by IRF-1. , 2005, Cancer research.

[126]  Shujian Wu,et al.  Activation of a cell-cycle-regulated histone gene by the oncogenic transcription factor IRF-2 , 1995, Nature.

[127]  T. Yamagata,et al.  ICSAT overexpression is not sufficient to cause adult T-cell leukemia or multiple myeloma. , 1999, Biochemical and biophysical research communications.

[128]  D. Kalvakolanu,et al.  The interferon-inducible murine p48 (ISGF3gamma) gene is regulated by protooncogene c-myc. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[129]  Stanley M Lemon,et al.  Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[130]  G. Hayward,et al.  The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation. , 2005, Immunity.

[131]  N. Satoh,et al.  Common deleted region on the long arm of chromosome 5 in esophageal carcinoma. , 1996, Gastroenterology.

[132]  L. Staudt,et al.  IRF4 addiction in multiple myeloma , 2008, Nature.

[133]  Taeil Kim,et al.  Activation of Interferon Regulatory Factor 3 in Response to DNA-damaging Agents* , 1999, The Journal of Biological Chemistry.

[134]  T. Taniguchi,et al.  A cell-type-specific requirement for IFN regulatory factor 5 (IRF5) in Fas-induced apoptosis , 2008, Proceedings of the National Academy of Sciences.

[135]  R. Clarke,et al.  Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer , 2010, Breast Cancer Research and Treatment.

[136]  M. Tainsky,et al.  Epigenetic Silencing of IRF7 and/or IRF5 in Lung Cancer Cells Leads to Increased Sensitivity to Oncolytic Viruses , 2011, PloS one.

[137]  Michael O. Kelleher,et al.  Regulation of the IRF-1 tumour modifier during the response to genotoxic stress involves an ATM-dependent signalling pathway , 2002, Oncogene.

[138]  Michael Karin,et al.  Inflammation meets cancer, with NF-κB as the matchmaker , 2011, Nature Immunology.

[139]  G. Sonenshein,et al.  Lysyl Oxidase Inhibits Ras-Mediated Transformation by Preventing Activation of NF-κB , 2003, Molecular and Cellular Biology.

[140]  Y. Miyagi,et al.  Genome-wide cDNA microarray screening of genes related to survival in patients after curative resection of non-small cell lung cancer. , 2006, Oncology reports.

[141]  K. Ozato,et al.  Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells. , 2007, Cancer research.

[142]  Sonia Sharma,et al.  Repression of IRF-4 target genes in human T cell leukemia virus-1 infection , 2002, Oncogene.